Comments
Ahmedabad-based drug maker, Intas Pharmaceuticals, today informed that the company has approached the Delhi High Court citing trademark violation by Arinna Lifesciences, and has got an ex-parte injunction against the sale of its anti-epilepsy drug Valrope.
In a statement issued on Wednesday, Intas claimed that Arinna's Valrope is similar to Intas’ well-established brand ‘Valprol’, which has been in the market since 1991.
Intas further stated that the court by its order has restrained "Arinna Lifesciences from using, advertising, marketing, selling or using on the Internet or as a domain name or in any manner whatsoever the trademark/name Valrope or any other mark/name which is identical and deceptively similar to Intas’ trademark Valprol till further orders''.
The court has also passed the order stating that Intas “has been able to make prima facie case for protection its trademark and if injunction is not granted, the organisation will suffer irreparable loss and injury,” the company statement said quoting the court order.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.